Menu
Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
100 Nagog Park
Acton, Massachusetts 01720-3440
Phone: 19786007000
www.myomnipod.com
SolarEdge, Insulet, and Dollar General returned the biggest losses of all stocks in the S&P 500 during the third quarter of 2023.
These are the stocks posting the largest moves in midday trading.
Insulet Corp. shares PODD gained 4% premarket on Monday after Jefferies analysts upgraded the stock to buy from hold, saying its valuation looks attractive after the shares were dragged down by fears that the weight-loss drug craze would hurt the insulin pump maker’s business. Diabetes stocks have been widely seen as risky due to the popularity of the diabetes and weight-loss treatments known as GLP-1s, yet the diabetes market remains large and underpenetrated, Jefferies analysts wrote in a note Monday. Insulet shares have been hit hard, dropping 45% in the year to date. But the company’s disposable patch pump is winning market share as it provides convenience to patients and recent trends in prescription data and physician feedback suggest that Insulet can deliver strong results in the coming quarters, the analysts wrote. The analysts have a $240 price target on the shares. Insulet said Monday that it will present extended real-world evidence on its Omnipod 5 automated insulin delivery system at the European Association for the Study of Diabetes annual meeting taking place this week in Hamburg.
Key learnings on Omnipod 5 and other data to be presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) Insulet Corporation (NASDAQ: PODD) (Insulet or the…
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced its schedule of events and presentations at EASD 2023, taking place today through October 6 in Hamburg, Germany, and online. The Company will present extended real-world evidence (RWE) of improved outcomes and optimization of care
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2023 on November 2, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor
https://www.investing.com/news/stock-market-news/insulets-financial-journey-marked-by-fed-rate-hikes-and-new-diabetes-treatments-93CH-3183581
